Designed, synthetically accessible bryostatin analogues potently induce activation of latent HIV reservoirs in vitro

Nature Chemistry

Volumn 4, Issue 9, 2012, Pages 705-710

  Dechristopher, Brian A ^a   Loy, Brian A ^a   Marsden, Matthew D ^b   Schrier, Adam J ^a   Zack, Jerome A ^b   Wender, Paul A ^a  

^a STANFORD UNIVERSITY   (United States)

^b UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTI HUMAN IMMUNODEFICIENCY VIRUS AGENT; BRYOSTATIN; PHORBOL ESTER; PROSTRATIN; PROTEIN KINASE C;

ANIMAL; ARTICLE; CELL LINE; CHEMICAL ENGINEERING; CHEMISTRY; DRUG DESIGN; DRUG EFFECT; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS; METABOLISM; PHYSIOLOGY; RAT; SYNTHESIS; VIRUS ACTIVATION;

ANIMALS; ANTI-HIV AGENTS; BRYOSTATINS; CELL LINE; CHEMICAL ENGINEERING; DRUG DESIGN; HIV; HUMANS; PHORBOL ESTERS; PROTEIN KINASE C; RATS; VIRUS ACTIVATION;

EID: 84866842026     PISSN: 17554330     EISSN: 17554349     Source Type: Journal    
DOI: 10.1038/nchem.1395     Document Type: Article

References (52)

1. Fauci, A. S. et al. HIV vaccine research: the way forward. Science 321, 530-532 (2008).
2. Davey, R. T. Jr et al. HIV-1 and T cell dynamics after interruption of highly active antiretroviral therapy (HAART) in patients with a history of sustained viral suppression. Proc. Natl Acad. Sci. USA 96, 15109-15114 (1999).
3. Carr, A. Toxicity of antiretroviral therapy and implications for drug development. Nature Rev. Drug Discov. 2, 624-634 (2003).
4. Mills, E. J. et al. Adherence to HAART: a systematic review of developed and developing nation patient-reported barriers and facilitators. PLoS Med. 3, 2039-2064 (2006).
5. Bangsberg, D. R. et al. High levels of adherence do not prevent accumulation of HIV drug resistance mutations. AIDS 17, 1925-1932 (2003).
6. Ruff, C. T. et al. Persistence of wild-type virus and lack of temporal structure in the latent reservoir for human immunodeficiency virus type 1 in pediatric patients with extensive antiretroviral exposure. J. Virol. 76, 9481-9492 (2002).
7. Bailey, J. R. et al. Residual human immunodeficiency virus type 1 viremia in some patients on antiretroviral therapy is dominated by a small number of invariant clones rarely found in circulating CD4 T cells. J. Virol. 80, 6441-6457 (2006).
8. Dinoso, J. B. et al. Treatment intensification does not reduce residual HIV-1 viremia in patients on highly active antiretroviral therapy. Proc. Natl Acad. Sci. USA 160, 9403-9408 (2009).
9. Coiras, M., Lopez-Huertas, M. R., Perez-Olmeda, M. & Alcami, J. Understanding HIV-1 latency provides clues for the eradication of long-term reservoirs. Nature Rev. 7, 798-812 (2009).
10. Finzi, D. et al. Latent infection of CD4 T cells provides a mechanism for lifelong persistence of HIV-1, even in patients on effective combination therapy. Nature Med. 5, 512-517 (1999).
11. Richman, D. D. et al. The challenge of finding a cure for HIV infection. Science 323, 1304-1307 (2009).
12. Stellbrink, H-J. et al. Effects of interleukin-2 plus highly active antiretroviral therapy on HIV-1 replication and proviral DNA (COSMIC trial). AIDS 16, 1479-1487 (2002).
13. Van Praag, R. M. E. et al. OKT3 and IL-2 treatment for purging of the latent HIV-1 reservoir in vivo results in selective long-lasting CD41 T cell depletion. J. Clin. Immunol. 21, 218-226 (2001).
14. Kulkosky, J. et al. Prostratin: activation of latent HIV-1 expression suggests a potential inductive adjuvant therapy for HAART. Blood 98, 3006-3015 (2001).
15. Korin, Y. D., Brooks, D. G., Brown, S., Korotzer, A. & Zack, J. A. Effects of prostratin on T-cell activation and human immunodeficiency virus latency. J. Virol. 76, 8118-8123 (2002).
16. Brow, S. J. & Hezarah, M. Methods of administering prostratin and structural analogs thereof. US patent no. 2009126949 (2009).
17. Wender, P. A., Kee, J-M. & Warrington, J. M. Practical synthesis of prostratin, DPP, and their analogs, adjuvant leads against latent HIV. Science 320, 649-652 (2008).
18. Pettit, G. R. et al. Isolation and structure of bryostatin 1. J. Am. Chem. Soc. 104, 6846-6848 (1982).
19. Kortmansky, J. & Schwartz, G. K. Bryostatin-1: a novel PKC inhibitor in clinical development. Cancer Invest. 21, 924-936 (2003).
20. Hale, K. J., Hummersone, M. G., Manaviazar, S. & Frigerio, M. The chemistry and biology of the bryostatin antitumour macrolides. Nat. Prod. Rep. 19, 413-453 (2002).
21. Etcheberrigaray, R. et al. Therapeutic effects of PKC activators in Alzheimer's disease transgenic mice. Proc. Natl Acad. Sci. USA 101, 11141-11146 (2004).
22. Kinter, A. L., Poli, G., Maury,W., Folks, T. M. & Fauci, A. S. Direct and cytokinemediated activation of protein kinase C induces human immunodeficiency virus expression in chronically infected promonocytic cells. J. Virol. 64, 4306-4312 (1990).
23. Quatsha, K. A., Rudolph, C., Marme, D., Schachtele, C. & May, W. S. Go 6976, a selective inhibitor of protein kinase C, is a potent antagonist of human immunodeficiency virus 1 induction from latent/low-level-producing reservoir cells in vitro. Proc. Natl Acad. Sci. USA 90, 4674-4676 (1993).
24. Mehla, R. et al. Bryostatin modulates latent HIV-1 infection via PKC and AMPK signaling but inhibits acute infection in a receptor independent manner. PLoS One 5, e11160 (2010).
25. Barr, P. M. et al. Phase II study of bryostatin 1 and vincristine for aggressive non- Hodgkin lymphoma relapsing after an autologous stem cell transplant. Am. J. Hematol. 84, 484-487 (2009).
26. Schaufelberger, D. E. et al. The large-scale isolation of bryostatin 1 from Bugula neritina following current good manufacturing practices. J. Nat. Prod. 54, 1265-1270 (1991).
27. Trindade-Silva, A. E., Lim-Fong, G. E., Sharp, K. H. & Haygood, M. G. Bryostatins: biological context and biotechnological prospects. Curr. Opin. Biotechnol. 21, 834-842 (2010).
28. Kageyama, M. et al. Synthesis of bryostatin 7. J. Am. Chem. Soc. 112, 7407-7408 (1990).
29. Evans, D. A. et al. Total synthesis of bryostatin 2. J. Am. Chem. Soc. 121, 7540-7552 (1999).
30. Ohmori, K. et al. Total synthesis of bryostatin 3. Angew. Chem. Int. Ed. 39, 2290-2294 (2000).
31. Trost, B. M. & Dong, G. Total synthesis of bryostatin 16 using atom-economical and chemoselective approaches. Nature 456, 485-488 (2008).
32. Keck, G. E., Poudel, Y. B., Cummins, T. J., Rudra, A. & Covel, J. A. Total synthesis of bryostatin 1. J. Am. Chem. Soc. 133, 744-747 (2011).
33. Wender, P. A. & Schrier, A. J. Total synthesis of bryostatin 9. J. Am. Chem. Soc. 133, 9228-9231 (2011).
34. Lu, Y., Woo, S. & Krische, M. J. Total synthesis of bryostatin 7 via C-C bond-forming hydrogenation. J. Am. Chem. Soc. 133, 13876-13879 (2011).
35. Wender, P. A. et al. Modeling of the bryostatins to the phorbol ester pharmacophore on protein kinase C. Proc. Natl Acad. Sci. USA 85, 7197-7201 (1988).
36. Wender, P. A. in Drug Discovery Research: New Frontiers in the Post-Genomic Era (ed. Huang, Z.) Ch. 6 (Wiley-VCH, 2007).
37. Wender, P. A., Loy, B. A. & Schrier, A. J. Translating nature's library: the bryostatins and function-oriented synthesis. Isr. J. Chem. 51, 453-472 (2011).
38. Wender, P. A., Verma, V. A., Paxton, T. J. & Pillow, T. H. Function-oriented synthesis, step economy, and drug design. Acc. Chem. Res. 41, 40-49 (2008).
39. Wender, P. A. et al. Synthesis of the first members of a new class of biologically active bryostatin analogues. J. Am. Chem. Soc. 120, 4534-4535 (1998).
40. Wender, P. A. et al. The practical synthesis of a novel and highly potent analogue of bryostatin. J. Am. Chem. Soc. 124, 13648-13649 (2002).
41. Wender, P. A., DeChristopher, B. A. & Schrier, A. J. Efficient synthetic access to a new family of highly potent bryostatin analogues via a Prins-driven macrocyclization strategy. J. Am. Chem. Soc. 130, 6658-6659 (2008).
42. Wender, P. A. et al. Design, synthesis, and evaluation of potent bryostatin analogs that modulate PKC translocation selectivity. Proc. Natl Acad. Sci. USA 108, 6721-6726 (2011).
43. Mackay, H. J. & Twelves, C. J. Targeting the protein kinase C family: are we there yet? Nature Rev. Cancer 7, 554-562 (2007).
44. DeChristopher, B. A., Fan, A. C., Felsher, D. W. & Wender, P. A. 'Picolog', a synthetically-available bryostatin analog, inhibits growth of MYC-induced lymphoma in vivo. Oncotarget 3, 58-66 (2012).
45. Khan, T. K., Nelson, T. J., Verma, V. A., Wender, P. A. & Alkon, D. L. A cellular model of Alzheimer's disease therapeutic efficacy: PKC activation reverses Ab-induced biomarker abnormality on cultured fibroblasts. Neurobiol. Dis. 34, 332-339 (2009).
46. Crane, E. A. & Scheidt, K. A. Prins-type macrocyclizations as an efficient ring-closing strategy in natural product synthesis. Angew. Chem. Int. Ed. 49, 8316-8326 (2010).
47. Krasovskiy, A., Kopp, F. & Knochel, P. Soluble lanthanide salts (LnCl3 .2LiCl) for the improved addition of organomagnesium reagents to carbonyl compounds. Angew. Chem. Int. Ed. 45, 497-500 (2006).
48. Marsden, M. D. & Zack, J. A. Establishment and maintenance of HIV latency: model systems and opportunities for intervention. Future Virol. 5, 97-109 (2010).
49. Jordan, A., Bisgrove, D. & Verdin, E. HIV reproducibly establishes a latent infection after acute infection in T cells in vitro. EMBO J. 22, 1868-1877 (2003).
50. Williams, S. A. et al. Prostratin antagonizes HIV latency by activating NF-kB. J. Biol. Chem. 279, 42008-42017 (2004).
51. Kovochich, M., Marsden, M. D. & Zack, J. A. Activation of latent HIV using drug-loaded nanoparticles. PLoS One 6, e18270 (2011).
52. Brooks, D. G. et al. Molecular characterization, reactivation, and depletion of latent HIV. Immunity 19, 413-423 (2003).